Last reviewed · How we verify
KHK7580
KHK7580 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway.
KHK7580 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway. Used for Thromboembolism prevention, Atrial fibrillation stroke prevention.
At a glance
| Generic name | KHK7580 |
|---|---|
| Also known as | evocalcet |
| Sponsor | Kyowa Kirin Co., Ltd. |
| Drug class | Factor XIa inhibitor |
| Target | Factor XIa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
KHK7580 selectively inhibits Factor XIa, an enzyme involved in the contact phase of blood coagulation. By blocking Factor XIa, the drug reduces the amplification of thrombin generation while potentially preserving hemostasis through the tissue factor pathway, which may provide a favorable safety profile with reduced bleeding risk compared to conventional anticoagulants.
Approved indications
- Thromboembolism prevention
- Atrial fibrillation stroke prevention
Common side effects
- Bleeding
- Gastrointestinal adverse events
Key clinical trials
- Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia (PHASE3)
- Pharmacokinetic Study of KHK7580 in Healthy Adult Volunteers (PHASE1)
- Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism (PHASE3)
- Phase 2 Study of KHK7580 (PHASE2)
- Phase 3 Study of KHK7580 (PHASE3)
- Phase 3 Study of KHK7580 (PHASE3)
- Phase 3 Study of KHK7580 (PHASE2, PHASE3)
- Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KHK7580 CI brief — competitive landscape report
- KHK7580 updates RSS · CI watch RSS
- Kyowa Kirin Co., Ltd. portfolio CI